Stonehage Fleming Financial Services Holdings Ltd Lowers Position in Edwards Lifesciences Co. (NYSE:EW)

Stonehage Fleming Financial Services Holdings Ltd trimmed its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 3.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,202,161 shares of the medical research company’s stock after selling 77,640 shares during the quarter. Edwards Lifesciences comprises about 4.6% of Stonehage Fleming Financial Services Holdings Ltd’s holdings, making the stock its 11th largest position. Stonehage Fleming Financial Services Holdings Ltd’s holdings in Edwards Lifesciences were worth $163,026,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of EW. FSA Wealth Management LLC bought a new stake in Edwards Lifesciences during the third quarter worth about $30,000. Prospera Private Wealth LLC purchased a new stake in Edwards Lifesciences in the third quarter worth approximately $32,000. Avior Wealth Management LLC grew its position in Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 308 shares during the last quarter. Peoples Bank KS purchased a new position in shares of Edwards Lifesciences during the third quarter worth approximately $40,000. Finally, JFS Wealth Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock worth $46,000 after acquiring an additional 166 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Price Performance

EW stock opened at $68.98 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The firm has a market capitalization of $40.68 billion, a price-to-earnings ratio of 9.95, a PEG ratio of 3.54 and a beta of 1.11. The firm has a 50 day moving average price of $72.33 and a 200-day moving average price of $70.52. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, hitting analysts’ consensus estimates of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The company’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.59 earnings per share. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Larry L. Wood sold 25,000 shares of Edwards Lifesciences stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at approximately $13,084,848.66. This trade represents a 11.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 500 shares of the firm’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total transaction of $34,380.00. Following the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 33,000 shares of company stock worth $2,195,180 in the last quarter. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

EW has been the topic of a number of analyst reports. Evercore ISI decreased their target price on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Stifel Nicolaus boosted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company a “hold” rating in a research note on Thursday, December 5th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their price objective on Edwards Lifesciences from $72.00 to $78.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, Sanford C. Bernstein raised shares of Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. One equities research analyst has rated the stock with a sell rating, fifteen have given a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $78.48.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.